Related Experiment Video
Updated: Aug 17, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
Stroke as a complication of congenital heart disease
Ji Y Chong1, Shunichi Homma, J P Mohr
1Doris and Stanley Tananbaum Stroke Center, Neurological Institute, Columbia University Medical Center, New York, NY 10032, USA.
Insights
Patent foramen ovale is common but may not increase recurrent stroke risk in medically treated patients. Current evidence does not support surgical or device closure for stroke prevention.
Area of Science:
- Cardiology
- Neurology
- Medical Devices
Background:
- Patent foramen ovale (PFO) is a frequent condition in the general population.
- PFO is linked to a higher risk of stroke.
- Optimal secondary stroke prevention strategies for patients with PFO remain debated.
Purpose of the Study:
- To review the current understanding of PFO's role in stroke.
- To evaluate evidence for different treatment modalities for stroke prevention in PFO patients.
- To address the ongoing questions regarding the best therapeutic approaches.
Main Methods:
- Review of existing clinical trial data.
- Analysis of studies comparing anticoagulation versus antiplatelet therapy.
- Assessment of evidence for interventional closure procedures.
Main Results:
- Antiplatelet therapy is supported by some data for secondary stroke prevention.
- Medical management may mitigate the increased stroke risk associated with PFO.
- Insufficient data exists to recommend surgical or percutaneous PFO closure for stroke prevention.
Conclusions:
- Antiplatelet therapy appears beneficial for secondary stroke prevention in patients with PFO.
- The role of PFO closure in stroke prevention requires further investigation.
- Current evidence favors medical management over procedural closure for PFO-associated stroke risk.
Abstract:
Patent foramen ovale is a common finding in the general population. It is associated with an increased risk of stroke, but it may not have a significant effect on recurrent stroke risk in medically treated patients. Recently, many questions have arisen with respect to best treatment for preventing recurrent stroke. Some data from a clinical trial of anticoagulation compared with antiplatelet therapy support antiplatelet treatment for secondary prevention. There are not enough data currently to support surgical or percutaneous closure of patent foramen ovale for stroke prevention.
Related Concept Videos
Hemorrhagic Stroke l: Introduction
Mitral Stenosis I: Introduction
Stroke: Introduction and Types
Hemorrhagic Stroke ll: Pathophysiology
Ischemic Stroke l: Introduction
Rheumatic Heart Disease I: Introduction

